13F
中

LYEL LYELL IMMUNOPHARMA INC

2026Q1 · CUSIP 55083R203 · Sector: Healthcare & Biotech

Neutral · No signal
Holders
72
Δ holders QoQ
+6
Breadth percentile
Top 39%
Whale holders
39
Δ whales
+5
Inst. holding value
$237M
New positions
18
Closed positions
12
Price momentum (1Q)
-34.9%
Put / Call
2/1

Breadth history (34 quarters)

2025Q3: Δ-8 · h=57 2025Q4: Δ+9 · h=66 2026Q1: Δ+6 · h=72 2025Q3: holders=57 2025Q4: holders=66 2026Q1: holders=72 -9 -4.5 +0 +4.5 +9 516476 25Q325Q426Q1 Δ holders (bar) Holders (line)

Past Lit Events & Aftermath 0 lit events

No lit events in history

Options Sentiment

Put holders
2
QoQ: -1
Call holders
1
QoQ: +1

See methodology →

Fundamentals

PE (TTM)
—
EPS (TTM)
$-13.62
EPS YoY
—
Revenue (TTM)
$0.0B
Revenue YoY
-52.3%
Quarterly Revenue & EPS (4Y)
2022-06-30: $36M 2022-09-30: $0M 2022-12-31: $48M 2023-03-31: $0M 2023-06-30: $0M 2023-09-30: $0M 2023-12-31: $0M 2024-03-31: $0M 2024-06-30: $0M 2024-09-30: $0M 2024-12-31: $0M 2025-03-31: $0M 2025-06-30: $0M 2025-09-30: $0M 2025-12-31: $0M 2026-03-31: $0M 2024-06-30: EPS -3.59 2024-09-30: EPS -3.48 2024-12-31: EPS -18.92 2025-03-31: EPS -3.54 2025-06-30: EPS -2.89 2025-09-30: EPS -2.13 2025-12-31: EPS -7.50 2026-03-31: EPS -1.10 0M 24M 48M $M -20.81 -10.41 0.00 20222023202420252026 Revenue EPS

Quarterly figures; EPS split-adjusted, early quarters hidden when not calibrable

As of 2026-03-31 · SEC filings (XBRL)